MXPA01013384A - Metodos para tratar diabetes. - Google Patents

Metodos para tratar diabetes.

Info

Publication number
MXPA01013384A
MXPA01013384A MXPA01013384A MXPA01013384A MXPA01013384A MX PA01013384 A MXPA01013384 A MX PA01013384A MX PA01013384 A MXPA01013384 A MX PA01013384A MX PA01013384 A MXPA01013384 A MX PA01013384A MX PA01013384 A MXPA01013384 A MX PA01013384A
Authority
MX
Mexico
Prior art keywords
methods
type
diabetes
symptoms
treating diabetes
Prior art date
Application number
MXPA01013384A
Other languages
English (en)
Inventor
Andreas Sommer
Original Assignee
Celtrix Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celtrix Pharma filed Critical Celtrix Pharma
Publication of MXPA01013384A publication Critical patent/MXPA01013384A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
MXPA01013384A 1999-06-04 2000-05-23 Metodos para tratar diabetes. MXPA01013384A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/326,189 US6040292A (en) 1999-06-04 1999-06-04 Methods for treating diabetes
PCT/US2000/014163 WO2000074710A2 (en) 1999-06-04 2000-05-23 Methods for treating diabetes

Publications (1)

Publication Number Publication Date
MXPA01013384A true MXPA01013384A (es) 2003-09-04

Family

ID=23271175

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA01013384A MXPA01013384A (es) 1999-06-04 2000-05-23 Metodos para tratar diabetes.

Country Status (16)

Country Link
US (1) US6040292A (es)
EP (1) EP1183042B1 (es)
JP (1) JP2003501397A (es)
KR (1) KR100694737B1 (es)
CN (1) CN1235637C (es)
AT (1) ATE271880T1 (es)
AU (1) AU780400B2 (es)
CA (1) CA2373281C (es)
DE (1) DE60012517T2 (es)
ES (1) ES2222208T3 (es)
HK (1) HK1044895A1 (es)
IL (1) IL146868A0 (es)
MX (1) MXPA01013384A (es)
NO (1) NO324117B1 (es)
WO (1) WO2000074710A2 (es)
ZA (1) ZA200110408B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6040292A (en) * 1999-06-04 2000-03-21 Celtrix Pharmaceuticals, Inc. Methods for treating diabetes
MY137552A (en) * 2000-07-03 2009-02-27 Bristol Myers Squibb Co Methods for treating rheumatic diseases using a soluble ctla4 molecule
US20040022787A1 (en) 2000-07-03 2004-02-05 Robert Cohen Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID
US20030035788A1 (en) * 2000-09-19 2003-02-20 Desmond Mascarenhas Method for use of IGF-binding protein for selective sensitization of target cells in vivo
US20040077679A1 (en) * 2002-07-29 2004-04-22 Cincotta Anthony H. Therapeutic treatment for the metabolic syndrome and type 2 diabetes
US20080200453A1 (en) 2002-07-29 2008-08-21 Cincotta Anthony H Methods of treating metabolic syndrome using dopamine receptor agonists
US20040220190A1 (en) * 2002-07-29 2004-11-04 Cincotta Anthony H. Methods of treating metabolic syndrome using dopamine receptor agonists
US9655865B2 (en) 2002-07-29 2017-05-23 Veroscience, Llc Therapeutic treatment for metabolic syndrome, type 2 diabetes, obesity, or prediabetes
US20040081678A1 (en) * 2002-08-09 2004-04-29 Anthony Cincotta Therapeutic process for the treatment of obesity and associated metabolic disorders
US8821915B2 (en) 2002-08-09 2014-09-02 Veroscience, Llc Therapeutic process for the treatment of the metabolic syndrome and associated metabolic disorders
US8137993B2 (en) * 2004-03-25 2012-03-20 Veroscience Llc Methods of identifying responders to dopamine agonist therapy and treating metabolic conditions thereof
US20050215558A1 (en) * 2004-03-25 2005-09-29 Cincotta Anthony H Methods of identifying responders to dopamine agonist therapy
US8137994B2 (en) * 2004-03-25 2012-03-20 Veroscience Llc Methods of identifying responders to dopamine agonist therapy and treating metabolic conditions thereof
WO2006074091A2 (en) * 2004-12-30 2006-07-13 Hill's Pet Nutrition, Inc. Compositions for feline consumption
EP2148695B1 (en) * 2007-04-18 2014-10-15 Premacure AB Method and product for treatment and/or prevention of complications of prematurity
EP2352514A4 (en) 2008-10-29 2012-07-25 Univ Rockefeller METHOD AND KIT FOR DISEASE TREATMENT BY ADMINISTRATION OF THE PROTEIN BINDING TO AN INSULINARY GROWTH FACTOR 2
AR075998A1 (es) 2009-04-01 2011-05-11 Genentech Inc Tratamiento de trastornos resistentes a insulina.composicion farmaceutica. uso. kit
US9352025B2 (en) 2009-06-05 2016-05-31 Veroscience Llc Combination of dopamine agonists plus first phase insulin secretagogues for the treatment of metabolic disorders
TR201809456T4 (tr) 2010-08-16 2018-07-23 Allergan Inc Alfa-2b adrenerjik reseptör agonistleri olan düzenleyici t hücrelerini aktifleştirme metodu.

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5200509A (en) * 1987-04-06 1993-04-06 Celtrix Pharmaceuticals, Inc. Human somatomedin carrier protein subunits and process for producing them; recombinant DNA molecules, hosts, processes and human somatomedin carrier protein-like polypeptides
US4988675A (en) * 1988-02-05 1991-01-29 Ciba-Geigy Corporation Method for preventing secondary effects
GB8920381D0 (en) * 1989-09-08 1989-10-25 Greater Glasgow Health Board Treatment of insulin-resistant diabetes
SE9201573D0 (sv) * 1992-05-19 1992-05-19 Kabi Pharmacia Ab Use of igf-1
GB9217696D0 (en) * 1992-08-20 1992-09-30 Agricultural & Food Res Use of specific binding molecules
US5407913A (en) * 1992-12-03 1995-04-18 Celtrix Pharmaceuticals, Inc. Method and composition for systemic treatment of tissue injury
JPH08500123A (ja) * 1993-01-25 1996-01-09 ザ ベス イスラエル ホスピタル アソシエイション Ｉｇｆ−ｉ感受性細胞のバリヤー特性の修飾方法，診断方法及びスクリーニング方法
US5563046A (en) * 1993-08-02 1996-10-08 Celtrix Pharmaceuticals, Inc. Fusion polypeptides and proteins
WO1995003817A1 (en) * 1993-08-03 1995-02-09 Celtrix Pharmaceuticals, Inc. Method of treating reproductive disorders
ATE297214T1 (de) * 1993-09-20 2005-06-15 Celtrix Pharma Behandlung von immunologischen und hematologischen störungen mit igfbp allein oder als komplex mit igf
CA2176709A1 (en) * 1993-11-15 1995-05-26 Howard R. Higley Method of treating renal disease by administering igf-i and igfbp-3
CA2176708A1 (en) * 1993-11-15 1995-05-26 Christopher A. Maack Method of treating neurological disorders
JPH10512235A (ja) * 1994-07-20 1998-11-24 セルトリックス ファーマシューティカルズ，インコーポレイテッド 骨形成の促進および骨再造形の調節のためのｉｇｆ／ｉｇｆｂｐ複合体
US5741776A (en) * 1995-05-22 1998-04-21 Genentech, Inc. Method of administration of IGF-I
US6436897B2 (en) * 1998-06-01 2002-08-20 Celtrix Pharmaceuticals, Inc. Pharmaceutical formulations for IGF/IGFBP
US6040292A (en) * 1999-06-04 2000-03-21 Celtrix Pharmaceuticals, Inc. Methods for treating diabetes

Also Published As

Publication number Publication date
EP1183042B1 (en) 2004-07-28
CN1387440A (zh) 2002-12-25
CA2373281A1 (en) 2000-12-14
WO2000074710A3 (en) 2001-06-28
JP2003501397A (ja) 2003-01-14
KR20020020723A (ko) 2002-03-15
DE60012517T2 (de) 2005-08-04
IL146868A0 (en) 2002-08-14
AU5041100A (en) 2000-12-28
HK1044895A1 (en) 2002-11-08
US6040292A (en) 2000-03-21
NO20015932D0 (no) 2001-12-04
DE60012517D1 (de) 2004-09-02
CA2373281C (en) 2010-01-12
NO324117B1 (no) 2007-08-27
ATE271880T1 (de) 2004-08-15
KR100694737B1 (ko) 2007-03-14
EP1183042A2 (en) 2002-03-06
AU780400B2 (en) 2005-03-17
WO2000074710A2 (en) 2000-12-14
CN1235637C (zh) 2006-01-11
ZA200110408B (en) 2003-03-19
ES2222208T3 (es) 2005-02-01
NO20015932L (no) 2002-01-31

Similar Documents

Publication Publication Date Title
ZA200110408B (en) Methods for treating diabetes.
PT1409006E (pt) Misturas monodispersas e métodos de tratamento de diabetes
MXPA04001525A (es) Analogos de peptido -1 similar al glucagon.
MY137350A (en) Glucagon-like peptide-1 analogs
NZ504258A (en) Exendin 3 and 4 agonist compounds for the treatment of diabetes
HK1022701A1 (en) Exendin analogues, processes for their preparationand medicaments containing them exendin.
NO20010982L (no) Fremgangsmåte for å administrere insulinotropiske peptider
SG127714A1 (en) Method of treating metabolic disorders, especiallydiabetes, or a disease or condition associated wi th diabetes
MY132626A (en) CARBAZOLYL-SUBSTITUTED ETHANOLAMINES AS SELECTIVE ß-3 AGONISTS
BR0308904A (pt) Método de tratamento de gastroparesia, e, uso de um composto de glp-1
UA88440C2 (ru) ЛЕЧЕНИЕ ГЛОМЕРУЛОНЕФРИТА И ХРОНИЧЕСКОЙ ПОЧЕЧНОЙ НЕДОСТАТОЧНОСТИ ПРИ ПОМОЩИ ИНТЕРФЕРОНА-β
LT2002063A (en) Low-dose metformin and gliburide combinations for treating diabetes
NO940180D0 (no) Anvendelse av IGF-I
BG104059A (en) Diabetes treatment with rosiglytazone and insulin
WO1999053064A3 (en) Methods of delivering glp-1
WO1999051216A3 (en) 3-pyridyloxyalkylamine or aryloxyalkylamine derivatives as cholinergic agonists
UA32255A (uk) Спосіб лікування цукрового діабету
GB9818650D0 (en) Therapeutic compounds and methods of making and using the same
UA32295A (uk) Спосіб лікування порушень фертильності у хворих на цукровий діабет
UA88862C2 (en) Glucagon-like peptide-1 analogs
UA32254A (uk) Спосіб лікування хронічного пієлонефриту у хворих на цукровий діабет
ECSP993116A (es) Procedimiento para administrar peptidos insulinotropicos

Legal Events

Date Code Title Description
FG Grant or registration